A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
Brief description of study
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
Clinical Study Identifier: s22-01005
ClinicalTrials.gov Identifier: NCT05384626
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
